Latest Insider Transactions at Bio Xcel Therapeutics, Inc. (BTAI)
This section provides a real-time view of insider transactions for Bio Xcel Therapeutics, Inc. (BTAI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BioXcel Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BioXcel Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2023
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,084
+50.0%
|
-
|
|
Jan 20
2023
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
29,713
-100.0%
|
$891,390
$30.0 P/Share
|
|
Jan 20
2023
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,713
+50.0%
|
$0
$0.41 P/Share
|
|
Jan 20
2023
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-85.62%
|
$1,500,000
$30.0 P/Share
|
|
Jan 05
2023
|
Krishnan Nandabalan Director |
SELL
Open market or private sale
|
Direct |
25,889
-98.45%
|
$569,558
$22.63 P/Share
|
|
Jan 05
2023
|
Krishnan Nandabalan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,889
+50.0%
|
$0
$0.41 P/Share
|
|
Jan 04
2023
|
Krishnan Nandabalan Director |
SELL
Open market or private sale
|
Direct |
34,111
-85.6%
|
$716,331
$21.9 P/Share
|
|
Jan 04
2023
|
Krishnan Nandabalan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
34,111
+50.0%
|
$0
$0.41 P/Share
|
|
Dec 16
2022
|
Vimal Mehta CEO and President |
SELL
Open market or private sale
|
Direct |
30,000
-50.08%
|
$570,000
$19.57 P/Share
|
|
Dec 16
2022
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+42.88%
|
$0
$0.41 P/Share
|
|
Dec 15
2022
|
Vimal Mehta CEO and President |
SELL
Open market or private sale
|
Direct |
30,000
-49.52%
|
$600,000
$20.03 P/Share
|
|
Dec 15
2022
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+42.88%
|
$0
$0.41 P/Share
|
|
Nov 11
2022
|
Krishnan Nandabalan Director |
SELL
Open market or private sale
|
Direct |
32,550
-100.0%
|
$488,250
$15.0 P/Share
|
|
Nov 11
2022
|
Krishnan Nandabalan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
32,550
+50.0%
|
$0
$0.41 P/Share
|
|
Nov 10
2022
|
Krishnan Nandabalan Director |
SELL
Open market or private sale
|
Direct |
27,450
-100.0%
|
$411,750
$15.0 P/Share
|
|
Nov 10
2022
|
Krishnan Nandabalan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
27,450
+50.0%
|
$0
$0.41 P/Share
|
|
Jun 25
2021
|
Bio Xcel Holdings, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
473,250
-5.25%
|
$14,197,500
$30.83 P/Share
|
|
Jun 25
2021
|
Bio Xcel LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
473,250
-5.25%
|
$14,197,500
$30.83 P/Share
|
|
Jun 25
2021
|
Krishnan Nandabalan Director |
SELL
Open market or private sale
|
Indirect |
473,250
-5.25%
|
$14,197,500
$30.83 P/Share
|
|
Jun 25
2021
|
Vimal Mehta CEO and President |
SELL
Open market or private sale
|
Indirect |
473,250
-5.25%
|
$14,197,500
$30.83 P/Share
|
|
Mar 15
2021
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,000
-10.32%
|
$720,000
$48.89 P/Share
|
|
Feb 17
2021
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
25,000
-53.71%
|
$1,375,000
$55.51 P/Share
|
|
Feb 17
2021
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+39.29%
|
$125,000
$5.71 P/Share
|
|
Feb 16
2021
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,000
-2.59%
|
$870,000
$58.53 P/Share
|
|
Feb 01
2021
|
Richard I Steinhart Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,750
-71.43%
|
$180,000
$48.15 P/Share
|
|
Feb 01
2021
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+41.67%
|
$18,750
$5.55 P/Share
|
|
Jan 25
2021
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,000
-3.82%
|
$720,000
$48.07 P/Share
|
|
Jan 25
2021
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.67%
|
$0
$0.41 P/Share
|
|
Jan 19
2021
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
25,000
-59.4%
|
$1,250,000
$50.4 P/Share
|
|
Jan 19
2021
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$0
$0.41 P/Share
|
|
Dec 28
2020
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
25,000
-70.57%
|
$1,300,000
$52.19 P/Share
|
|
Dec 28
2020
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$0
$0.41 P/Share
|
|
Jul 24
2020
|
Bio Xcel LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
160,000
-1.74%
|
$9,600,000
$60.76 P/Share
|
|
Jul 24
2020
|
Bio Xcel Holdings, Inc. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
160,000
-100.0%
|
$9,600,000
$60.76 P/Share
|
|
Jul 24
2020
|
Bio Xcel Holdings, Inc. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
160,000
+50.0%
|
$9,600,000
$60.76 P/Share
|
|
Jul 24
2020
|
Bio Xcel Holdings, Inc. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
160,000
-1.74%
|
$9,600,000
$60.76 P/Share
|
|
Jul 24
2020
|
Krishnan Nandabalan Director |
BUY
Other acquisition or disposition
|
Direct |
80,000
+50.0%
|
$4,800,000
$60.76 P/Share
|
|
Jul 24
2020
|
Krishnan Nandabalan Director |
SELL
Other acquisition or disposition
|
Indirect |
160,000
-1.74%
|
$9,600,000
$60.76 P/Share
|
|
Jul 24
2020
|
Vimal Mehta CEO and President |
BUY
Other acquisition or disposition
|
Direct |
80,000
+50.0%
|
$4,800,000
$60.76 P/Share
|
|
Jul 24
2020
|
Vimal Mehta CEO and President |
SELL
Other acquisition or disposition
|
Indirect |
160,000
-1.74%
|
$9,600,000
$60.76 P/Share
|
|
Apr 01
2019
|
Krishnan Nandabalan Director |
BUY
Bona fide gift
|
Indirect |
1,000
+50.0%
|
-
|
|
Apr 01
2019
|
Krishnan Nandabalan Director |
SELL
Bona fide gift
|
Direct |
1,000
-100.0%
|
-
|
|
Mar 12
2018
|
Vimal Mehta CEO and President |
BUY
Open market or private purchase
|
Indirect |
2,000
+50.0%
|
$22,000
$11.0 P/Share
|